IP Library Granted Patent US 11,186,621
Granted Patent B2
US 11,186,621 · App. 16/405,863 · Granted Nov 30, 2021

Methods for enhancing the pluripotency of stem cells

Inventors: Minoru S. H. Ko (Cockeysville, MD); Tomokazu Amano (Parkville, MD)
Assignees: Elixirgen, LLC; The U.S. of America, as Represented by the Secretary for the Department of Health and Human Service
C07K14/47C07K14/70567C07K14/721C12N5/0606C12N5/0696C12N15/62C12N15/79C12N15/85C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,621
App. No.
16/405,863
Granted
Nov 30, 2021
Kind
B2
Abstract

Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. As the potency increases, even a whole animal can be produced from a single ES cell injected into a 4N blastocyst at an unexpectedly high success rate. The studies disclosed herein indicate that ES cells acquire higher potency by going through the transient Zscan4 activation state more frequently than the regular state. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins. Further provided are methods of prolonging and/or enhancing stem cell pluripotency using the disclosed Zscan4-ERT2 nucleic acid molecules and fusion proteins.

Claims (8)

1. An in vitro method of prolonging pluripotency, increasing frequency of Zscan4-positive cells and/or increasing telomere length of a mouse embryonic stem (ES) cell, the method comprising:

a) transfecting an expression vector comprising a nucleic acid encoding a Zscan4-ΔC protein consisting of the amino acid sequence as set forth in SEQ ID NO:25 into the mouse ES cell; and

b) culturing the transfected mouse ES cell in culture medium such that the Zscan4-ΔC protein is expressed in the mouse ES cell.

2. An in vitro method of prolonging pluripotency, increasing frequency of Zscan4-positive cells and/or increasing telomere length of a mouse embryonic stem (ES) cell, the method comprising:

a) transfecting an expression vector comprising a nucleic acid encoding a Zscan4-ERT2 fusion protein consisting of the amino acid sequence as set forth in SEQ ID NO:22 or SEQ ID NO:23 into the mouse ES cell; and

b) culturing the transfected mouse ES cell in culture medium lacking tamoxifen such that the Zscan4-ERT fusion protein is expressed in the mouse ES cell.

3. The method of claim 2 , wherein the Zscan4-ERT2 fusion protein consists of the amino acid sequence of SEQ ID NO:23.

4. The method of claim 2 , wherein the Zscan4-ERT2 fusion protein consists of the amino acid sequence of SEQ ID NO:22.

Assignments (4)
CHANGE OF NAME Recorded Jun 11, 2026
From: ELIXIRGEN, LLC
To: ENGINS, LLC
Reel/Frame 075712/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2021
From: THE UNITED STATES OF AMERICA, AS RESPRESENTED BY THE SECRETARY FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
To: KO, MINORU, DR.
Reel/Frame 057104/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: KO, MINORU S.H.; AMANO, TOMOKAZU
To: THE UNITED STATES OF AMERICA, SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 052753/0779 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: KO, MINORU SHIL HONG
To: ELIXIRGEN, LLC
Reel/Frame 052755/0492 →
Continuity (3)
Division 14006954
Provisional Application 61466667 · Mar 23, 2011
Related Publication 20190330288A1 · Oct 31, 2019